Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arrowhead Pharmaceuticals Enters Exclusive License Agreement with GSK for ARO-HSD
- Upon closing, Arrowhead to receive $120 million upfront payment for Phase 1/2 program for NASH - Arrowhead eligible to receive potential milestone payments and royalties on commercial sales - GSK to receive an exclusive license for ARO-HSD in all territories except Greater China PASADENA, Calif.
View HTML
Toggle Summary Arrowhead Announces JNJ-75220795 in Development for NASH
PASADENA, Calif. --(BUSINESS WIRE)--Nov. 17, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that its collaborator, Janssen Pharmaceuticals, Inc. , (Janssen) one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has disclosed its collaboration with Arrowhead on
View HTML
Toggle Summary Arrowhead Collaborator Presents Phase 2b Clinical Data from REEF-1 Study in Patients with Chronic Hepatitis B Infection
PASADENA, Calif. --(BUSINESS WIRE)--Nov. 15, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) collaborator Janssen Pharmaceuticals, Inc. , one of the Janssen Pharmaceutical Companies of Johnson & Johnson, presented clinical data from REEF-1, a Phase 2b study of different combination regimens,
View HTML
Toggle Summary Arrowhead Presents New Clinical Data on ARO-APOC3 at AHA 2021
PASADENA, Calif. --(BUSINESS WIRE)--Nov. 15, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced additional Phase 1/2 clinical data on ARO-APOC3, the company’s investigational RNA interference (RNAi) therapeutic targeting apolipoprotein C-III (APOC3) being developed as a treatment
View HTML
Toggle Summary Arrowhead Presents Additional Clinical Data on Investigational ARO-HSD Treatment at AASLD Liver Meeting
PASADENA, Calif. --(BUSINESS WIRE)--Nov. 12, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced additional interim clinical data from AROHSD1001, an ongoing Phase 1/2 clinical study of ARO-HSD, the company’s investigational RNA interference (RNAi) therapeutic being developed as a
View HTML
Toggle Summary Arrowhead Presents Additional Clinical Data on Investigational ARO-AAT Treatment at AASLD Liver Meeting
PASADENA, Calif. --(BUSINESS WIRE)--Nov. 12, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced additional interim clinical data from the ongoing AROAAT2002 study, an open-label Phase 2 clinical study of ARO-AAT, also known as TAK-999, the company’s second-generation
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Year End Results
PASADENA, Calif. --(BUSINESS WIRE)--Nov. 1, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 22, 2021 , at 4:30 p.m. ET to discuss its financial results for the fiscal year ended September 30, 2021 .
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Participate in Upcoming November 2021 Conferences
PASADENA, Calif. --(BUSINESS WIRE)--Nov. 1, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: The Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD) – November
View HTML
Toggle Summary Arrowhead Files for Regulatory Clearance to Begin Phase 1/2a Study of ARO-C3 for Treatment of Complement Mediated Diseases
- KOL Webinar Tomorrow, October 26, 2021 at 3:00 p.m. ET PASADENA, Calif. --(BUSINESS WIRE)--Oct. 25, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to begin a Phase 1/2a clinical trial of ARO-C3, the company’s investigational RNA
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinar on ARO-C3 for Treatment of Complement Mediated Diseases
PASADENA, Calif. --(BUSINESS WIRE)--Oct. 12, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that on October 26, 2021 , at 3:00 p.m. ET it will host a key opinion leader (KOL) webinar on ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic being developed
View HTML